MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Cytokinetics, Incorporated ROCE Ratio 2011-2026 | CYTK
Annual ROCE Ratio Cytokinetics, Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 396.13 | 128.44 | 300.47 | -76.4 | -82.85 | -37.48 | -47.05 | -43.22 | 13.65 | -44.75 | -13.52 | -60.01 | -57.51 | -97.08 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 396.13 | -97.08 | 19.92 |
Quarterly ROCE Ratio Cytokinetics, Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1132.81 | 980.9 | 982.52 | 951.96 | -23.55 | 150.72 | 797.58 | 1448.45 | 1402.05 | 602.0 | 574.22 | -132.31 | -454.87 | -419.97 | -415.4 | -383.04 | -79.25 | -50.74 | 168.03 | 382.23 | 655.04 | 687.22 | 618.14 | 330.3 | -4.26 | -260.11 | -285.99 | -242.79 | -175.45 | -69.98 | -33.99 | 27.89 | 39.15 | 11.66 | -1.3 | -50.25 | -54.02 | -41.39 | -47.9 | -41.46 | -35.15 | -25.17 | -48.34 | -64.99 | -83.53 | -74.07 | -88.44 | -79.65 | -64.75 | -41.33 | -63.48 | -71.25 | -86.79 | -74.86 | -22.14 | -28.33 | -24.39 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1448.45 | -454.87 | 135.06 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K |  USA |
 |
Adagene
ADAG
|
-46.22 | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.62 | 1.91 % | $ 8.71 B |  Australia |
 |
Biogen
BIIB
|
31.45 | $ 172.5 | 0.53 % | $ 25.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 117.41 | 1.23 % | $ 27.2 B | Germany |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Catalyst Biosciences
CBIO
|
424.75 | $ 12.1 | -5.47 % | $ 797 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
-20.47 | $ 4.16 | -5.88 % | $ 116 M | France |
 |
BioXcel Therapeutics
BTAI
|
72.23 | $ 1.79 | -1.92 % | $ 4.54 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-104.07 | $ 2.98 | -3.75 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 231.73 | -1.55 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
14.24 | $ 9.72 | -0.31 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.53 | $ 67.09 | 0.06 % | $ 8.97 B | USA |
 |
Compugen Ltd.
CGEN
|
-15.7 | $ 2.05 | -2.15 % | $ 184 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 4.41 | -1.34 % | $ 9.6 B | Israel |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.28 | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-353.66 | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
28.05 | $ 26.4 | 1.85 % | $ 1.28 B | USA |
 |
Coherus BioSciences
CHRS
|
105.05 | $ 2.27 | 10.19 % | $ 214 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
10.81 | $ 13.54 | 1.12 % | $ 4.18 B | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
-225.02 | - | - | $ 269 M | USA |
 |
Celldex Therapeutics
CLDX
|
-26.11 | $ 26.48 | 2.16 % | $ 1.71 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.73 | 1.11 % | $ 17.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
11.12 | $ 94.12 | 1.25 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |